IRVINE, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

WASHINGTON, DC—Transcatheter tricuspid valve repair with the Pascal system (Edwards Lifesciences) significantly reduces tricuspid regurgitation (TR) with durable outcomes at 1 year, according to new ...

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from ...

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PHILADELPHIA — Six-month data from the CLASP study ...

Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences announced its precision transcatheter mitral valve repair system for edge-to-edge repair ...

Progress continues to be made on new transcatheter devices for the treatment of severe mitral and tricuspid regurgitation, investigators reported. Several valve repair and replacement technologies, ...

CHICAGO -- Compassionate use of the Pascal leaflet repair system on patients with severe tricuspid regurgitation resulted in some successes, according to first-in-human data presented here. Neil Fam, ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...